XPC基因rs2228000(C/T)多态性与乳腺癌易感性的Meta分析

doi:10.3760/cma.j.issn.1673-422X.2016.10.008

摘要/Abstract

摘要： 目的定量探讨着色性干皮病C组（XPC）基因rs2228000(C/T)多态性与乳腺癌易感性之间的关系。方法通过计算机检索PubMed、Cochrane Library、中国生物医学文献数据库(CBM)、万方医药期刊全文数据库、中国期刊全文数据库(CNKI)及维普数据库（VIP），检索时间截至2015年12月，搜集有关XPC rs2228000(C/T)位点多态性与乳腺癌风险的病例对照研究。采用STATA 12.0软件进行结果分析，计算比值比（OR）和95%CI。结果总共纳入8篇文献，包括9个病例对照研究（3 850例乳腺癌患者和5 047例健康对照）。纯合子模型（TT vs. CC：OR=1.28，95%CI为1.08～1.52，Z=2.80，P=0.005）和隐性模型(TT vs. TC+CC：OR=1.23，95%CI为1.05～1.43，Z=2.64，P=0.008）中XPC rs2228000(C/T)多态性与乳腺癌易感性有关，而等位基因模型、杂合子模型、显性基因模型中XPC rs2228000(C/T)位点多态性与乳腺癌风险无关（P＞0.05）。在亚洲人群和PCRRFLP亚组的4种基因模型中，XPC rs2228000(C/T)多态性与乳腺癌易感性有关（T vs. C：OR=1.21，95%CI为1.05～1.40，Z=2.63，P=0.009；TT vs. CC：OR=1.55，95%CI为1.13～2.13，Z=2.70，P=0.007；TT+TC vs. CC：OR=1.26，95%CI为1.02～1.55，Z=2.19，P=0.028；TT vs. TC+CC：OR=1.39，95%CI为1.04～1.87，Z=2.23，P=0.026）。基于对照组来源的亚组分析，社区来源的纯合子模型中XPC rs2228000(C/T)多态性与乳腺癌发病风险有关（TT vs. CC：OR=1.27，95%CI为1.02～1.57，Z=2.16，P=0.031）。结论XPC rs2228000(C/T)多态性可能与乳腺癌风险有关，尤其在亚洲人群中，基因型TT可能增加乳腺癌发病风险。

关键词: 乳腺肿瘤, 单核苷酸, 多态性, Meta分析, 着色性干皮病C组基因

Abstract: ObjectiveTo quantitatively examine the relationship between xeroderma pigmentosum complementation C group (XPC) rs2228000(C/T) polymorphism and the susceptibility of breast cancer. MethodsThe relevant casecontrol studies published up to December 2015 which investigated XPC rs2228000(C/T) polymorphism and breast cancer risk were identified by searching PubMed, Cochrane Library, Chinese Biomedical Literature Data, Wanfang Database, China National Knowledge Infrastructure and VIP Database. Metaanalysis was conducted using STATA 12.0 software and odds ratio (OR) with its 95%CI were estimated. ResultsA total of 8 researches involving 9 casecontrol studies (3 850 breast cancer cases and 5 047 healthy controls) were included. The Metaanalysis showed that there was statistical association between XPC rs2228000(C/T) variance and breast cancer risk in the homozygous model (TT vs. CC: OR=1.28, 95%CI: 1.081.52, Z=2.80, P=0.005) and recessive model (TT vs. TC+CC: OR=1.23, 95%CI: 1.051.43, Z=2.64, P=0.008), but not in the allele model, heterozygote model and dominant model. In the subgroup of ethnicity and genotyping methods, the different significant correlation was existed between them under Asian and PCRRFLP in genetic models (T vs. C: OR=1.21, 95%CI: 1.051.40, Z=2.63, P=0.009; TT vs. CC: OR=1.55, 95%CI: 1.132.13, Z=2.70, P=0.007; TT+TC vs. CC: OR=1.26, 95%CI: 1.021.55, Z=2.19, P=0.028; TT vs. TC+CC: OR=1.39, 95%CI: 1.041.87, Z=2.23, P=0.026). We also found significant association between them in subgroup of populationbased controls in the homozygous model (TT vs. CC: OR=1.27, 95%CI: 1.021.57, Z=2.16, P=0.031). ConclusionXPC rs2228000(C/T) polymorphism may be associated with the susceptibility of breast cancer, especially in Asian, and genetype TT may increase the risk of breast cancer.

Key words: Breast neoplasms, Polymorphism, single nucleotide, Metaanalysis, Xeroderma pigmentosum complementation C group gene

崔静,谭辉,姜雷,袁文臻,关泉林. XPC基因rs2228000(C/T)多态性与乳腺癌易感性的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(10): 752-757.

Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC rs2228000(C/T) polymorphism and the susceptibility of breast cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(10): 752-757.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［3］ Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes［J］. Biochim Biophys Acta, 2015, 1856(1): 73-85. DOI: 10.1016/j.bbcan.2015.06.002. ［4］ Amir E, Seruga B, Serrano R, et al. Targeting DNA repair in breast cancer: a clinical and translational update［J］. Cancer Treat Rev, 2010, 36(7): 557-565. DOI: 10.1016/j.ctrv.2010.03.006. ［5］ Thoms KM, Kuschal C, Emmert S. Lessons learned from DNA repair defective syndromes［J］. Exp Dermatol, 2007, 16(6): 532-544. DOI: 10.1111/j.16000625.2007.00559.x. ［6］ Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease［J］. Nat Clin Pract Neurol, 2007, 3(3): 162-172. DOI: 10.1038/ncpneuro0448. ［7］ O′driscoll M, Jeggo PA. The role of doublestrand break repairinsights from human genetics［J］. Nat Rev Genet, 2006, 7(1): 45-54. DOI: 10.1038/nrg1746. ［8］吴雪铭, 马韵, 龙喜带. DNA修复基因XPC研究进展［J］. 右江民族医学院学报, 2009, 31(5): 876-878. DOI: 10.3969/j.issn.10015817.2009.05.088. ［9］ Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms［J］. DNA Repair (Amst), 2008, 7(2): 141-148. DOI: 10.1016/j.dnarep.2007.08.006. ［10］陈泽鑫, 刘慧, 潘益峰, 等. 试验性和观察性研究相关医学文献质量评价方法［J］. 中国循证医学杂志, 2011, 11(11): 1229-1236. DOI: 10.3969/j.issn.16722531.2011.11.002. ［11］ PérezMayoral J, PachecoTorres AL, Morales L, et al. Genetic polymorphisms in RAD23B and XPC modulate DNA repair capacity and breast cancer risk in Puerto Rican women［J］. Mol Carcinog, 2013, 52(Suppl 1): E127-E138. DOI: 10.1002/mc.22056. ［12］ Yang X, Liu D, Wu H, et al. Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients［J］. Cancer Sci, 2012, 103(7): 1207-1214. DOI: 10.1111/j.13497006.2012.02312.x. ［13］ Roberts MR, Shields PG, Ambrosone CB, et al. Singlenucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study［J］. Carcinogenesis, 2011, 32(8): 1223-1230. DOI: 10.1093/carcin/bgr096. ［14］吴茵茵, 马新源, 姚开颜, 等. XPC基因Lys939Gln和Ala499Val多态性与乳腺癌易感性的关联研究［J］. 浙江大学学报(医学版), 2011, 40(3): 252-258. DOI: 10.3785/j.issn.10089292.2011.03.004. ［15］ Shen J, Gammon MD, Terry MB, et al. Xeroderma pigmentosum complementation group C genotypes/diplotypes play no independent or interaction role with polycyclic aromatic hydrocarbonsDNA adducts for breast cancer risk［J］. Eur J Cancer, 2008, 44(5): 710-717. DOI: 10.1016/j.ejca.2007.10.027. ［16］ Smith TR, Levine EA, Freimanis RI, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk［J］. Carcinogenesis, 2008, 29(11): 2132-2138. DOI: 10.1093/carcin/bgn193. ［17］ Jorgensen TJ, Visvanathan K, Ruczinski I, et al. Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland［J］. Breast Cancer Res Treat, 2007, 101(1): 65-71. ［18］ Shen J, Desai M, Agrawal M, et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer［J］. Cancer Epidemiol Biomarkers Prev, 2006, 15(9): 1614-1619. DOI: 10.1158/10559965.EPI060218. ［19］ Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005［J］. Mutat Res, 2005, 577(1/2): 275-283. DOI: 10.1016/j.mrfmmm.2005.03.007. ［20］ Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review［J］. J Natl Cancer Inst, 2000, 92(11): 874-897. ［21］ Jani′cijevi′c A, Sugasawa K, Shimizu Y, et al. DNA bending by the human damage recognition complex XPCHR23B［J］. DNA Repair (Amst), 2003, 2(3): 325-336. ［22］ Thoma BS, Vasquez KM. Critical DNA damage recognition functions of XPChHR23B and XPARPA in nucleotide excision repair［J］. Mol Carcinog, 2003, 38(1): 1-13. DOI: 10.1002/mc.10143. ［23］ Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)PDNA adducts in a sample of healthy subjects［J］. Carcinogenesis, 2001, 22(9): 1437-1445. ［24］ Wang Y, Li Z, Liu N, et al. Association between CCND1 and XPC polymorphisms and bladder cancer risk: a metaanalysis based on 15 casecontrol studies［J］. Tumour Biol, 2014, 35(4): 3155-3165. DOI: 10.1007/s1327701314129. ［25］ PaszkowskaSzczur K, Scott RJ, Górski B, et al. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population［J］. Mol Biol Rep, 2015, 42(3): 755-764. DOI: 10.1007/s110330143824z. ［26］ PaszkowskaSzczur K, Scott RJ, SerranoFernandez P, et al. Xeroderma pigmentosum genes and melanoma risk［J］. Int J Cancer, 2013, 133(5): 1094-1100. DOI: 10.1002/ijc.28123.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.